Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Side-effect incidence of different doses of Kanglaite capsule as postoperative adjuvant therapy in early non-small cell lung cancer
ChiCTR2200058310Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2022
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of kanglaite in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Adverse events. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
kanglaite
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200058310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058310.